# Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

> **NCT00506155** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Avastin
- **DRUG:** Cisplatin
- **DRUG:** Doxorubicin
- **DRUG:** Methotrexate
- **DRUG:** Vinblastine Sulfate

## Key facts

- **NCT ID:** NCT00506155
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506155, "Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00506155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*